Amarin
Ballsbridge · Founded 1991
About Amarin
Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease. Amarin’s lead candidate, AMR101, is currently being studied in two concurrently run pivotal Phase 3 trials. These trials are investigating the efficacy of AMR101 in lowering triglycerides in patients with very high triglycerides (>500mg/dl) and in patients with mixed dyslipidemia who are taking statins. Amarin’s cardiovascular programs capitalize on Amarin's expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease. Amarin is headquartered in Dublin, Ireland, and has its research and development headquartered in Mystic Connecticut, USA. Amarin is listed in the U.S. on NASDAQ (ticker: AMRN)
Company Facts
- Founded: 1991
- Legal name: Amarin Pharmaceuticals Ireland Limited.
- Operating status: IPO
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Total funding: $227.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2015)
- Website: amarincorp.com
- Phone: +353 1 669 9020
Social Profiles
Canonical: https://fsome.com/organization/amarin-8437732 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.